Wells Fargo & Company MN increased its position in shares of National Research Co. (NASDAQ:NRCIA) by 75.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,450 shares of the business services provider’s stock after buying an additional 4,056 shares during the quarter. Wells Fargo & Company MN’s holdings in National Research were worth $356,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in NRCIA. Citigroup Inc. raised its position in shares of National Research by 120.2% during the 2nd quarter. Citigroup Inc. now owns 8,299 shares of the business services provider’s stock valued at $224,000 after buying an additional 4,531 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of National Research by 252.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 9,090 shares of the business services provider’s stock valued at $244,000 after buying an additional 6,508 shares during the period. Alliancebernstein L.P. raised its position in shares of National Research by 5.1% during the 2nd quarter. Alliancebernstein L.P. now owns 12,369 shares of the business services provider’s stock valued at $333,000 after buying an additional 600 shares during the period. Teachers Advisors LLC raised its position in shares of National Research by 36.6% during the 2nd quarter. Teachers Advisors LLC now owns 17,691 shares of the business services provider’s stock valued at $476,000 after buying an additional 4,736 shares during the period. Finally, Macquarie Group Ltd. purchased a new stake in shares of National Research during the 3rd quarter valued at approximately $488,000. 25.19% of the stock is currently owned by hedge funds and other institutional investors.
In other news, CEO Michael D. Hays sold 1,602,399 shares of the company’s stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $39.03, for a total transaction of $62,541,632.97. Following the sale, the chief executive officer now owns 5,261,410 shares of the company’s stock, valued at $205,352,832.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 37.54% of the stock is currently owned by corporate insiders.
Shares of National Research Co. (NASDAQ:NRCIA) traded up $0.60 during midday trading on Friday, reaching $35.05. The company’s stock had a trading volume of 17,258 shares, compared to its average volume of 16,623. The stock has a market capitalization of $858.09, a price-to-earnings ratio of 70.10 and a beta of 1.54. National Research Co. has a 52 week low of $16.90 and a 52 week high of $41.99.
The business also recently disclosed a quarterly dividend, which was paid on Friday, January 12th. Stockholders of record on Friday, December 29th were given a dividend of $0.10 per share. This represents a $0.40 dividend on an annualized basis and a dividend yield of 1.14%. The ex-dividend date of this dividend was Thursday, December 28th. National Research’s dividend payout ratio is currently 80.00%.
A number of analysts have issued reports on the company. Zacks Investment Research raised National Research from a “sell” rating to a “hold” rating in a research report on Tuesday, February 6th. BidaskClub lowered National Research from a “buy” rating to a “hold” rating in a research report on Friday, January 19th.
National Research Profile
National Research Corporation, doing business as NRC Health, is a provider of analytics and insights for healthcare providers, payers and other healthcare organizations. The Company operates through six segments: Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Connect.
Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.